Arizona, AHCCCS and GLP-1s

What changed, and what the document says

1. The state employee plan, on weight loss

   Not covered

   The plan that covers active and retired state workers pays for several GLP-1s, and excludes the indication most shoppers are asking about.

   “The plan does not cover any drug solely for the purpose of weight loss/obesity.”

   Arizona Joint Legislative Budget Committee — November 25, 2025

2. What it spends anyway

   Context

   The exclusion is about the indication, not the molecule — the same plan's diabetes spending on this drug class runs into eight figures.

   “In Plan Year 2025, spending on GLP-1s was $28 M.”

   Arizona Joint Legislative Budget Committee — November 25, 2025

3. Per person, per year

   Context

   Budget staff published the per-member figure rather than only the total, which is the number a cash shopper can actually compare against.

   “Average annual amount paid per member was $8,637.”

   Arizona Joint Legislative Budget Committee — November 25, 2025

4. Medicaid's rule, in the agency's own slide

   Not covered

   The Medicaid agency told the committee directly where it stands, and the committee printed the slide in its final report.

   “AHCCCS currently does not cover GLP-1 for the treatment of obesity.”

   Arizona State Legislature, Obesity Treatment Study Committee — December 2025

5. The single carve-out the agency names

   Conditions apply

   One drug, one purpose, and a prior authorization — the heart-risk indication survives where the weight indication does not.

   “AHCCCS also covers 1 GLP-1 Receptor Agonist (Wegovy) in specific circumstances to reduce the risk of major adverse cardiovascular events when medically necessary and approved via prior authorization.”

   Arizona State Legislature, Obesity Treatment Study Committee — December 2025

6. What the change was priced at

   Context

   A fiscal note on a bill that would have required comprehensive obesity coverage put a range on it and then warned readers about the range.

   “we estimate the full-year cost of providing coverage of anti-obesity medication could range from $962.9 million-$2.5 billion on a Total Funds basis”

   Arizona Joint Legislative Budget Committee Staff — 2/20/24

7. What the committee asked for in the end

   Context

   Three recommendations came out of the hearings. The first one is a definition, not a benefit.

   “Officially recognize obesity as a chronic disease.”

   Arizona State Legislature, Obesity Treatment Study Committee — December 2025

Which of these companies serve Arizona?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

25 of those lists name Arizona: Red Mountain Weight Loss, Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, ZYP Medical, The Virtual NP, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, MEDvidi, PCOS Sisters, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.